Search Results - "Wernsing, Margaret"

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study by Teerlink, John R., Voors, Adriaan A., Ponikowski, Piotr, Pang, Peter S., Greenberg, Barry H., Filippatos, Gerasimos, Felker, G. Michael, Davison, Beth A., Cotter, Gad, Gimpelewicz, Claudio, Boer‐Martins, Leandro, Wernsing, Margaret, Hua, Tsushung A., Severin, Thomas, Metra, Marco

“…Patients admitted for acute heart failure (AHF) experience high rates of in‐hospital and post‐discharge morbidity and mortality despite current therapies…”
Get full text

Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension by Philipp, Thomas, MD, Smith, Timothy R., MD, RPh, Glazer, Robert, MD, Wernsing, Margaret, BS, Yen, Joseph, PhD, Jin, James, PhD, Schneider, Helmut, MD, Pospiech, Rainer, MD

“…Abstract Background: Patients with hypertension may require combination therapy to attain the blood pressure targets recommended by US and European treatment…”
Get full text

Amlodipine and Valsartan Combined and as Monotherapy in Stage 2, Elderly, and Black Hypertensive Patients: Subgroup Analyses of 2 Randomized, Placebo‐Controlled Studies by Smith, Timothy R., Philipp, Thomas, Vaisse, Bernard, Bakris, George L., Margaret Wernsing, Yen, Joseph, Glazer, Robert

“…Patients with difficult to control hypertension typically require 2 or more agents to achieve goal blood pressure (BP) levels. Fixed‐dose combination therapies…”
Get full text

Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension by Poldermans, Don, MD, Glazes, Robert, MD, Kargiannis, Stefanos, MD, Wernsing, Margaret, BS, Kaczor, Jeanne, LPN, Chiang, Yann Tong, PhD, Yen, Joseph, PhD, Gamboa, Raul, MD, Fomina, Irina, MD, PhD

“…Abstract Background: Most patients with hypertension in the United States and Europe fail to achieve the recomended target blood pressure (BP) of <140/90 mm…”
Get full text

Initial combination therapy with amlodipine/valsartan compared with monotherapy in the treatment of hypertension by Philipp, Thomas, Glazer, Robert D, Wernsing, Margaret, Yen, Joseph

“…Achieving target blood pressure (BP) is influenced by baseline BP. Post hoc analyses of a placebo-controlled trial of amlodipine/valsartan versus monotherapies…”
Get more information

Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics by Jering, Karola S., Claggett, Brian, Pfeffer, Marc A., Granger, Christopher, Køber, Lars, Lewis, Eldrin F., Maggioni, Aldo P., Mann, Douglas, McMurray, John J.V., Rouleau, Jean‐Lucien, Solomon, Scott D., Steg, Philippe G., Meer, Peter, Wernsing, Margaret, Carter, Katherine, Guo, Weinong, Zhou, Yinong, Lefkowitz, Martin, Gong, Jianjian, Wang, Yi, Merkely, Bela, Macin, Stella M., Shah, Urmil, Nicolau, Jose C., Braunwald, Eugene

“…Aims Patients surviving an acute myocardial infarction (AMI) are at risk of developing symptomatic heart failure (HF) or premature death. We hypothesized that…”
Get full text

Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies by Howard, Campbell, Noe, Adele, Skerjanec, Andrej, Holzhauer, Björn, Wernsing, Margaret, Ligueros-Saylan, Monica, Thuren, Tom

“…We aimed to assess the safety and tolerability of different doses of canakinumab versus placebo in patients with type 2 diabetes mellitus (T2DM). Data were…”
Get full text

Safety and tolerability of canakinumab, an IL-1[beta] inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies by Howard, Campbell, Noe, Adele, Skerjanec, Andrej, Holzhauer, Björn, Wernsing, Margaret, Ligueros-Saylan, Monica, Thuren, Tom

“…Doc number: 94 Abstract Background: We aimed to assess the safety and tolerability of different doses of canakinumab versus placebo in patients with type 2…”
Get full text